380 related articles for article (PubMed ID: 31694167)
1. Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma.
Calabretta E; d'Amore F; Carlo-Stella C
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31694167
[TBL] [Abstract][Full Text] [Related]
2. Hodgkin lymphoma: targeting the tumor microenvironment as a therapeutic strategy.
Montanari F; Diefenbach CS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):518-24. PubMed ID: 26351815
[TBL] [Abstract][Full Text] [Related]
3. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
Bair SM; Mato A; Svoboda J
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424
[TBL] [Abstract][Full Text] [Related]
5. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
Carlo-Stella C; Santoro A
Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?
Lin RJ; Diefenbach CS
Oncology (Williston Park); 2016 Oct; 30(10):914-20. PubMed ID: 27753058
[TBL] [Abstract][Full Text] [Related]
7. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance.
Aldinucci D; Celegato M; Casagrande N
Cancer Lett; 2016 Sep; 380(1):243-52. PubMed ID: 26474544
[TBL] [Abstract][Full Text] [Related]
8. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
Liu WR; Shipp MA
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):310-316. PubMed ID: 29222272
[TBL] [Abstract][Full Text] [Related]
9. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
[TBL] [Abstract][Full Text] [Related]
10. Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma.
Wein F; Weniger MA; Höing B; Arnolds J; Hüttmann A; Hansmann ML; Hartmann S; Küppers R
Cancer Immunol Res; 2017 Dec; 5(12):1122-1132. PubMed ID: 29070649
[TBL] [Abstract][Full Text] [Related]
11. Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
Younes A; Ansell SM
Semin Hematol; 2016 Jul; 53(3):186-9. PubMed ID: 27496310
[TBL] [Abstract][Full Text] [Related]
12. Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It.
Aldinucci D; Borghese C; Casagrande N
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31096713
[TBL] [Abstract][Full Text] [Related]
13. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.
Aldinucci D; Gloghini A; Pinto A; De Filippi R; Carbone A
J Pathol; 2010 Jul; 221(3):248-63. PubMed ID: 20527019
[TBL] [Abstract][Full Text] [Related]
14. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
Vardhana S; Younes A
Haematologica; 2016 Jul; 101(7):794-802. PubMed ID: 27365459
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma.
Bennani-Baiti N; Thanarajasingam G; Ansell S
Expert Rev Clin Immunol; 2016 Jun; 12(6):673-9. PubMed ID: 26818843
[TBL] [Abstract][Full Text] [Related]
16. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
Reinke S; Bröckelmann PJ; Iaccarino I; Garcia-Marquez M; Borchmann S; Jochims F; Kotrova M; Pal K; Brüggemann M; Hartmann E; Sasse S; Kobe C; Mathas S; Soekler M; Keller U; Bormann M; Zimmermann A; Richter J; Fuchs M; von Tresckow B; Borchmann P; Schlößer H; von Bergwelt-Baildon M; Rosenwald A; Engert A; Klapper W
Blood; 2020 Dec; 136(25):2851-2863. PubMed ID: 33113552
[TBL] [Abstract][Full Text] [Related]
17. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis.
Carbone A; Gloghini A; Caruso A; De Paoli P; Dolcetti R
Int J Cancer; 2017 Mar; 140(6):1233-1245. PubMed ID: 27750386
[TBL] [Abstract][Full Text] [Related]
18. Novel agents in the therapy of Hodgkin lymphoma.
Ansell S
Am Soc Clin Oncol Educ Book; 2015; ():e479-82. PubMed ID: 25993212
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.
Ansell SM
Cancer J; 2018; 24(5):249-253. PubMed ID: 30247261
[TBL] [Abstract][Full Text] [Related]
20. Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment.
Carbone A; Gloghini A; Pruneri G; Dolcetti R
Cancer Med; 2019 Jun; 8(6):3012-3016. PubMed ID: 31070022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
